Figure 4. Antigenic characterization of ML designed LASV GPC constructs.
(A) Protein yield of 24 lead designs (with high pLDDT confidence predictions). (B) Fold change compared to GPC-CysR4-I53A for designs from panel A. (C) Antigenic profile of all 24 designs with a panel of conformation specific monoclonal antibodies.